Zoe Johnson

Zoe Johnson

Company: iOnctura

Job title: Chief Scientific Officer

Seminars:

Panel Discussion: Making PI3K Inhibitors Work in the Clinic 3:00 pm

• Developing effective combination strategies • Targeting beyond the PI3K pathway • Disease specific resistance mechanisms • Isoform specific vs Pan PI3K inhibitors in mitigating resistanceRead more

day: Day One

Selective Targeting of PI3Kδ for the Treatment of Solid Tumors: Immune Mediated & Direct Anti-Cancer Activity 12:00 pm

• IOA-244 is a novel PI3Kδ inhibitor with a unique binding mode, conferring an excellent safety profile • IOA-244 is in clinical development for the treatment of solid tumors burdened by an immune suppressive TME and characterised by high PI3Kδ expression • The potential of IOA-244 is also being exploring as a safer PI3Kδ inhibitor…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.